The goal of this clinical study is to determine the effectiveness of restoring muscle strength in the management of motor inhibition when complemented by the ALLYANE process (neuro-motor reprogramming) compared to a standard management approach.

The main questions it aims to answer are:

• Does the ALLYANE process lead to greater muscle strength gains compared to standard care?
• Is there a functional benefit when standard management is complemented by the ALLYANE process?

The investigators will compare the group receiving standard care complemented by ALLYANE to a group receiving only standard care to evaluate if the ALLYANE process provides additional effects.

Participants will:

• Undergo assessments of muscle strength.
• Receive either standard management or standard management with ALLYANE.
• Complete functional evaluations before and after treatment.

This study aims to evaluate the effectiveness of motor inhibition management using two different approaches: standard management alone and standard management supplemented by the ALLYANE neuro-motor reprogramming process. To ensure robust and reliable results, the study proposes enrolling a total of 120 patients, divided into two groups of 60 patients each.

Inclusion Criteria:

• Men and women aged 18 to 35 years
• No neurological history
• Have had a primary knee sprain
• Present with VMO lateralisation with or without the presence of flessum
• Quadricipital weakness between the healthy and injured limb of 50% or more as measured by a portable dynamometer
• Member of a social security scheme

Exclusion Criteria:

• Recurrent sprain
• Bilateral sprain
• Persons under guardianship, trusteeship or any other measure depriving them of their rights or liberty, and adults protected by law.
• Persons who do not understand French
• Knee trauma other than sprain
• Exclusion criteria for the Allyane procedure (COPHOSIS, cognitive difficulties, purely mechanical limitation)
• Algodystrophy

The shared IPD will include key data points such as demographic information, muscle strength assessment results, functional evaluation scores, and patient-reported outcomes like Lysholm Questionnaire results. Personal identifiers will be removed to ensure participant confidentiality. Data sharing will adhere to ethical and legal requirements. Specifically, the individual participant data sets underlying results in a publication will be shared.

The IPD and supporting information will be made available starting after statistical analysis is complete and during the process of writing the manuscript for publication. The data will remain accessible for a period of three years following the publication of the study results.

Access to the IPD and supporting information will be granted to qualified researchers affiliated with academic, governmental, or non-profit institutions. They will have access to de-identified individual participant data, including demographic details, muscle strength assessments, functional evaluation results, and patient-reported outcomes. Access will be provided through a secure repository or data-sharing platform after approval of a data-sharing agreement. Researchers must agree to use the data solely for academic and non-commercial purposes, comply with all ethical guidelines, and acknowledge the source in any resulting publications.